

# Hepatoblastoma in a child with neurofibromatosis type I

## Nörofibromatozis tip I'de hepatoblastom olgusu

Uğur IŞIK,<sup>1</sup> Cengiz CANPOLAT<sup>2</sup>

<sup>1</sup>Department of Child Health and Diseases, Division of Pediatric Neurology, Acibadem University Faculty of Medicine, İstanbul

<sup>2</sup>Department of Child Health and Diseases, Division of Pediatric Hematology-Oncology, Acibadem University Faculty of Medicine, İstanbul

A major hallmark of neurofibromatosis type I (NFI) is the development of benign tumors. Hepatoblastomas associated with NFI is reported rarely in the literature. We present here a one year-old girl with both NFI and hepatoblastoma. Hepatoblastoma can be associated with NFI. Abdominal ultrasound is not included within the diagnostic criteria or surveillance of NFI. As NFI can be associated with hepatoblastoma and other abdominal tumors, a careful physical examination and an abdominal USG if necessary should be considered.

**Keywords:** Hepatoblastoma; neurofibromatosis type I.

Nörofibromatozis tip I'in (NFI) en önemli bulgularından biri selim tümörlerdir. Bu hastalıkta hepatoblastom görülmesi literatürde çok nadir olarak bildirilmiştir. Burada Nörofibromatozis tip I ve hepatoblastomu olan bir yaşında bir kız çocuğu sunulmaktadır. Hepatoblastom nörofibromatozis tip I ile birlikte görülebilir. Nörofibromatozis tip I'de hepatoblastom ve diğer batin içi tümörler görülebileceğinden dikkatli bir fizik bakı ve gerekirse batin ultrasonografi yapılması gereklidir.

**Anahtar sözcükler:** Hepatoblastom; nörofibromatozis tip I.

Neurofibromatosis (NF) type I is one of the most common genetic disorders in the general population with approximately 1 in 3500 people.<sup>[1]</sup> Diagnostic criteria consists of; two or more of the following seven features; 1- Six or more café au lait spots (1.5 cm or larger in postpubertal individuals, 0.5 cm or larger in prepubertal individuals), 2- Two or more neurofibromas of any type or one or more plexiform neurofibromas 3- Freckling of armpits or groin 4- Optic glioma (tumor of the optic pathway), 5- Two or more Lisch nodules (benign iris hamartomas), 6- A distinctive bony lesion (dysplasia of sphenoid bone, dysplasia or thinning of long bone cortex) 7- First degree relative with NF.<sup>[2]</sup>

A population study from Japan of 26.084 children younger than 15 years revealed a six to eight fold increased incidence of cancer in NF1 patients.<sup>[3]</sup> Malignant peripheral nerve sheath tumors repre-

sent the most common neoplasm in approximately 5–10% of individuals with NFI.<sup>[4]</sup> Children with NFI have an increased risk of Wilm's tumor and myeloid leukemias, including acute myeloblastic leukemia, myelodysplasia and myeloproliferative syndromes.<sup>[5,6]</sup> In addition neuroblastoma has been reported in patients with NFI.<sup>[7]</sup> Other malignancies occur less frequently in patients with NF1, including pheochromocytoma, rhabdomyosarcoma and brain tumors other than optic gliomas.<sup>[8]</sup> There is only one case report of NFI associated with hepatoma and one with hepatoblastoma in the literature.<sup>[9,10]</sup>

### CASE REPORT

A one year old girl living in a European country who was recently diagnosed with NFI presented to our child neurology clinic for a second-opinion. She was born full-term with a birth weight of 3730

Presented at the 16<sup>th</sup> National Child Neurology Congress (2014 Kapadokya, Turkey).

Correspondence (İletişim): Dr. Uğur IŞIK. Acibadem Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Pediatrik Nöroloji Bilim Dalı, İstanbul, Turkey.  
Tel: +90 - 216 - 571 44 71 e-mail (e-posta): ugur.isik@acibadem.com.tr


© 2015 Türk Radyasyon Onkolojisi Derneği - © 2015 Turkish Society for Radiation Oncology

grams, with no difficulties. She sat up at the age of 8 months and started to walk at the age of 11 months. She spoke 3–4 words at the time of examination. She was a healthy 1 year-old girl with no complaints related with her abdomen. In her examination she had 15 cafe au lait spots more than 0.5 cm in diameter. She had no axillary or inguinal freckling, no osseous lesions or cutaneous neurofibromas. An abdominal mass was palpated at the right upper quadrant. She had the genetic confirmation as well because she did not fulfill the requirement for a definitive NFI. Her ophthalmological examination did not show any findings. MRI of the brain was performed and did not show any abnormalities. Her abdominal USG showed a solitary non-homogeneous mass with peripheral hypoechoic rim in the posterior right lobe of the liver in segment 7. It was confirmed with abdominal MRI (Fig 1) that showed 56x40 mm T2 hyperintense, T1 hypointense mass with diffusion restriction and with heterogeneous contrast enhancement suggestive of a malignant lesion. The patient's family decided to have surgery in the the country they currently live. The pathology report revealed hepatoblastoma.

## DISCUSSION

Although primary hepatic cancers are rare in children, they are the third most frequent abdominal solid tumor in children. Two major types of hepatic cancer in infants and children have been described, hepatoblastoma and hepatocellular carcinoma (hepatoma). Hepatoblastoma is usually found in children younger than the age of 4 years and hepatocellular carcinoma usually occurs in children older than 6 years.<sup>[9]</sup> Both hepatoma and hepatoblastoma were found in NFI patients.<sup>[9,10]</sup>

To establish the extent of disease in an individual diagnosed with NFI, the following evaluations are recommended: Personal medical history with particular attention to features of NFI, physical examination with particular attention to the skin, skeleton, cardiovascular system, and neurologic systems, ophthalmologic evaluation including slit lamp examination of the irides, developmental assessment in children, other studies only as indicated on the basis of clinically apparent signs or symptoms, genetics consultation.<sup>[11,12]</sup>



**Fig. 1.** 56x40 mm T1 hypointense mass in the right lobe segment 7, with diffusion restriction and heterogeneous contrast enhancement.

The surveillance of NFI consists of annual physical examination by a physician who is familiar with the disease, annual ophthalmologic examination in early childhood, less frequent examination in older children and adults, regular developmental assessment by screening questionnaire (in childhood), regular blood pressure monitoring, other studies only as indicated on the basis of clinically apparent signs or symptoms, monitoring of those who have abnormalities of the central nervous system, skeletal system, or cardiovascular system by an appropriate specialist.<sup>[11,12]</sup> As NFI can be associated with hepatoblastoma and other abdominal tumors, a careful physical examination and an abdominal USG if necessary, should be considered.

## REFERENCES

1. Hersh JH. American Academy of Pediatrics Committee on Genetics. Health supervision for children with neurofibromatosis. *Pediatrics* 2008;121(3):633–42.
2. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. *JAMA* 1997 Jul 2;278(1):51–7. [CrossRef](#)
3. Matsui I, Tanimura M, Kobayashi N, Sawada T, Nagahara N, Akatsuka J. Neurofibromatosis type 1 and childhood cancer. *Cancer* 1993;72(9):2746–54. [CrossRef](#)
4. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. *J Med Genet* 2002;39(5):311–4. [CrossRef](#)
5. Bader JL, Miller RW. Neurofibromatosis and childhood

- leukemia. *J Pediatr* 1978;92(6):925–9. [CrossRef](#)
6. Brodeur GM. The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. *N Engl J Med* 1994;330(9):637–9. [CrossRef](#)
  7. Origone P, Defferrari R, Mazzocco K, Lo Cunsolo C, De Bernardi B, Tonini GP. Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma. *Am J Med Genet A* 2003;118A(4):309–13. [CrossRef](#)
  8. Hope DG, Mulvihill JJ. Malignancy in neurofibromatosis. *Adv Neurol* 1981;29(1):33–56.
  9. Ettinger LJ, Freeman AI. Hepatoma in a child with neurofibromatosis. *Am J Dis Child* 1979;133(5):528–31.
  10. Uçar C, Caliřkan U, Toy H, Günel E. Hepatoblastoma in a child with neurofibromatosis type I. *Pediatr Blood Cancer* 2007;49(3):357–9. [CrossRef](#)
  11. Neurofibromatosis 1. Friedman JM In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. *GeneReviews™* [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2013. 1998.
  12. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. *J Med Genet* 2007;44(2):81–8. [CrossRef](#)